WO2021215769A1 - 비침습적 뇌자극 헬스케어 장치 - Google Patents
비침습적 뇌자극 헬스케어 장치 Download PDFInfo
- Publication number
- WO2021215769A1 WO2021215769A1 PCT/KR2021/004893 KR2021004893W WO2021215769A1 WO 2021215769 A1 WO2021215769 A1 WO 2021215769A1 KR 2021004893 W KR2021004893 W KR 2021004893W WO 2021215769 A1 WO2021215769 A1 WO 2021215769A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- electrode
- recipient
- unit
- band
- helmet
- Prior art date
Links
- 230000000638 stimulation Effects 0.000 title claims abstract description 81
- 210000004556 brain Anatomy 0.000 title claims abstract description 53
- 230000036541 health Effects 0.000 title abstract description 14
- 210000003128 head Anatomy 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 24
- 210000001152 parietal lobe Anatomy 0.000 claims description 16
- 210000001652 frontal lobe Anatomy 0.000 claims description 14
- 210000000869 occipital lobe Anatomy 0.000 claims description 8
- 210000003478 temporal lobe Anatomy 0.000 claims description 8
- 230000001936 parietal effect Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 4
- 210000001061 forehead Anatomy 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 23
- 208000010877 cognitive disease Diseases 0.000 description 19
- 208000027061 mild cognitive impairment Diseases 0.000 description 18
- 230000006872 improvement Effects 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 10
- 230000006993 memory improvement Effects 0.000 description 10
- 230000035882 stress Effects 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 239000008199 coating composition Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 230000003373 anti-fouling effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000009226 cognitive therapy Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 244000020998 Acacia farnesiana Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 201000006347 Intellectual Disability Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 244000272264 Saussurea lappa Species 0.000 description 2
- 235000006784 Saussurea lappa Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000010482 emotional regulation Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/332—Portable devices specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0456—Specially adapted for transcutaneous electrical nerve stimulation [TENS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0476—Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36031—Control systems using physiological parameters for adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0484—Garment electrodes worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/08—Arrangements or circuits for monitoring, protecting, controlling or indicating
Definitions
- the embodiment relates to a non-invasive brain stimulation healthcare device.
- Mild cognitive impairment refers to a state in which memory or other cognitive functions are clearly diminished enough to be confirmed by objective tests, but the ability to carry out daily life is preserved and is not yet dementia.
- mild cognitive impairment is a high-risk group for dementia. It is known that about 1 to 2% of the normal elderly progress to dementia every year, but about 10 to 15% of those with mild cognitive impairment progress to dementia every year. In the case of mild cognitive impairment, approximately 80% of patients with mild cognitive impairment progress to dementia after 6 years, so they are in the high-risk group for dementia.
- Treatment methods for mild cognitive impairment include drug therapy, cognitive therapy, and brain stimulation therapy.
- Alzheimer's disease treatment As drug treatment, Alzheimer's disease treatment, ginkgo leaf extract, choline precursor, vitamin B group supplement, etc. can be used, and if depression is the cause, antidepressants are sometimes used.
- antidepressants are sometimes used.
- Cognitive therapy is a cognitive rehabilitation for the brain function of a degraded area, and corresponds to a treatment for improving cognitive deficits and improving social function using scientific learning principles.
- cognitive therapy has a problem that it takes a long time to improve and the effect is weak.
- Brain stimulation treatment includes invasive treatment such as deep brain stimulation and non-invasive treatment that stimulates the brain from the outside with magnetism, electricity, or ultrasound.
- invasive treatment has a risk of side effects or complications after surgery, so research on non-invasive treatment is being actively conducted.
- Non-invasive treatment of mild cognitive impairment does not show immediate effect compared to invasive treatment, but has the advantage of having fewer side effects and a significant effect compared to cognitive treatment.
- a representative example of non-invasive treatment is a method using transcranial current stimulation (tCS), and specifically, a method of activating a specific part of the recipient's brain or causing rest with tDCS (transcranial direct current stimulation). This is widely used.
- tCS transcranial current stimulation
- tDCS transcranial direct current stimulation
- Treatment using tDCS is less effective when the patient's tension or stress is high.
- tDCS causes discomfort such as a stinging pain in the skin at the beginning of the procedure, and this discomfort lowers the periodic and long-term availability of the recipient's health care system, and even if used, there is a problem of increasing the patient's tension or stress.
- the method of using electrical stimulation which is a representative example of non-invasive treatment of mild cognitive impairment, is to apply electrical stimulation with electrodes in close contact with the scalp.
- electrical stimulation there is for example, it is difficult to position the plurality of electrodes of the electrical stimulation device at an appropriate position, and there are problems such as preventing adhesion of the electrodes by hair.
- the embodiment provides a brain stimulation healthcare device that can prevent and effectively treat mild cognitive impairment.
- the embodiment provides a non-invasive brain stimulation healthcare device with improved electrode adhesion and wearability that can be directly worn by a recipient.
- the embodiment provides a non-invasive brain stimulation healthcare system that can further improve the treatment effect by lowering the patient's tension or stress.
- a non-invasive brain stimulation healthcare device for solving the above-described problem includes a plurality of electrode units for applying electrical stimulation to the brain of a recipient; a power supply unit for supplying power to the plurality of electrode units; and a controller for controlling the electrical stimulation applied to the brain of the recipient by controlling the plurality of electrodes and the power supply, wherein the electrical stimulation includes a buffer mode using tACS and a main mode using tDCS.
- the buffer mode may be performed before the main mode is performed.
- the control unit collects information about the ECG of the recipient from the sensor unit, and the control unit analyzes the information on the ECG of the recipient and ends the buffer mode when the recipient is in a normal state,
- the main mode may be performed.
- the plurality of electrode units may include: a first electrode unit for applying electrical stimulation to a left frontal lobe of the brain of the recipient; a second electrode unit for applying electrical stimulation to the right frontal lobe of the subject's brain; a third electrode unit for applying electrical stimulation to the left parietal lobe of the brain of the recipient; a fourth electrode unit for applying electrical stimulation to the right parietal lobe of the brain of the recipient; and a fifth electrode portion disposed on the head of the recipient and having a polarity different from that of the first to fourth electrode portions.
- the upper electrode adhesion module includes: a first band adjustment unit having a fixed position and installed on the helmet; and a first band, the length of which is adjusted by the first band adjusting unit, and configured as a ring to surround the head of the recipient from the inside of the helmet, wherein at least a portion of the plurality of electrode units includes the first band is installed, and when the length of the first band is shortened by the first band adjusting unit, the electrode unit installed in the first band may be in close contact with the frontal lobe side of the recipient.
- At least some of the plurality of electrode parts are installed on the inner rear side of the helmet, and when the length of the first band is shortened by the first band adjusting part, the electrode part installed on the inner rear part of the helmet is located on the parietal and occipital lobes of the recipient. It may be supported in close contact with an area including at least a part of the side and the temporal lobe side.
- Another part of the plurality of electrode parts may be installed at a position capable of adhering to a region including at least a portion of the parietal lobe side, the occipital lobe side, and the temporal lobe side of the recipient of the first band.
- the electrode part includes a wet pad
- the helmet has a first frame formed to cover from the forehead to the back of the head, and having an opening at the top, and a second frame extending upward from the first frame and crossing the head of the recipient. Including, moisture or moisture generated in the wet pad may be discharged through the opening.
- An LED monitoring unit for displaying an operation state of the electrode unit may be installed on the helmet.
- the recipient can safely stimulate the brain.
- the recipient can easily wear it alone.
- the recipient wears a helmet and operates the first dial in a state in which the third and fourth electrodes are in close contact with the region including at least a portion of the parietal, occipital, and temporal lobes to operate the first electrode and the second electrode.
- the electrode unit may be in close contact with the frontal lobe
- the fifth electrode unit may be in close contact with a region including at least a portion of the back of the ear, the back of the head, and the back of the neck by manipulating the second dial.
- the portion where the first to fourth electrode parts are installed is opened, so that the moisture evaporation problem caused by the use of the wet electrode can be solved.
- the invasive brain stimulation healthcare system can reduce pain due to skin stimulation of tDCS by operating the buffer mode before the start of the main mode or between consecutive main modes.
- FIG. 1 is a schematic structural diagram of a healthcare system according to an embodiment of the present invention.
- FIGS. 2 to 5 are schematic reference diagrams for explaining various electrical stimulation of the healthcare system according to an embodiment of the present invention.
- FIG. 6 schematically shows the form of electrical stimulation of tDCS and tACS.
- FIG. 7 is a reference diagram for explaining a check mode, a buffer mode, and a main mode of the healthcare system according to an embodiment of the present invention.
- FIG. 8 is a schematic reference diagram illustrating an example of a program of a healthcare system according to an embodiment of the present invention.
- 9 to 11 are quantitative EEG data before and after the procedure of the healthcare system according to an embodiment of the present invention.
- FIG. 12 is a schematic side view of a healthcare device in which a healthcare system according to an embodiment of the present invention is implemented.
- FIG. 13 is a schematic rear view of a healthcare device according to another embodiment of the present invention.
- FIG. 14 is a schematic bottom view of a healthcare device according to another embodiment of the present invention.
- 15A is a schematic plan view of an upper electrode adhesion module of a healthcare device according to another embodiment of the present invention.
- 15B is a schematic perspective view of the inside of a helmet of a healthcare device according to another embodiment of the present invention.
- 16 is a schematic plan view of a lower electrode adhesion module of a healthcare device according to another embodiment of the present invention.
- module may include a unit implemented in hardware, software, or firmware, and may be used interchangeably with terms such as, for example, logic, logic block, component, or circuit.
- a module may be an integrally formed part or a minimum unit or a part of the part that performs one or more functions.
- a “module” or “node” performs operations such as moving, storing, and converting data by using an arithmetic device such as a CPU or AP.
- a “module” or “node” may be implemented as a device such as a server, PC, tablet PC, smartphone, or the like.
- Non-invasive brain stimulation healthcare system includes
- FIG. 1 is a schematic structural diagram of a non-invasive brain stimulation healthcare system (hereinafter, referred to as a “health care system”) according to an embodiment of the present invention.
- the healthcare system 100 is configured to non-invasively apply electrical stimulation through an electrode in close contact with the scalp of the recipient. Through such electrical stimulation, it is possible to prevent, treat, and manage various diseases caused by the brain. For example, by using the healthcare system 100 according to an embodiment of the present invention, not only mild cognitive impairment, but also depression, convulsive disease, pain, memory improvement, motor learning ability improvement, intellectual disability, addiction disease, schizophrenia, etc. can be prevented, treated and managed.
- the healthcare system 100 includes a plurality of electrode units 110 , a power supply unit 120 , a sensor unit 130 , and a control unit 140 .
- the healthcare system 100 of the present invention is implemented by a non-invasive brain stimulation healthcare device to be described later, so that a recipient can easily use the healthcare system 100 .
- a non-invasive brain stimulation healthcare device according to another embodiment of the present invention will be described in detail later.
- the plurality of electrode units 110 are in close contact with various positions of the subject's head.
- the plurality of electrode units 110 may receive power from the power supply unit 120 to allow current to flow.
- Some of the plurality of electrode units 110 may be positive electrodes, and others may be negative electrodes.
- the first electrode unit 111 is in close contact with a position corresponding to the left frontal lobe of the subject's head
- the second electrode unit 113 is in close contact with a position corresponding to the right frontal lobe of the subject's head
- the third electrode unit 115 is in close contact with a position corresponding to a region including at least some of the left parietal lobe, left occipital lobe, and left temporal lobe of the recipient's head
- the fourth electrode unit 117 is located on the right parietal and right occipital lobe of the recipient's head. It is closely adhered to a position corresponding to an area including at least a part of the lateral and right temporal lobe sides.
- first to fourth electrode units 111 , 113 , 115 , and 117 current may flow by the power supplied from the power supply unit 120 .
- the first to fourth electrode parts 111 , 113 , 115 , and 117 may be either a positive electrode through which current is emitted or a negative electrode through which current is received.
- the fifth electrode unit 119 may be in close contact with the subject's head at a different position from the first to fourth electrode units 111 , 113 , 115 , and 117 , and for example, among the recipient's ears, the back of the head, and the back of the neck. It may be in close contact with the region including at least a part. In this case, the fifth electrode unit 119 may be either a positive electrode through which current is emitted or a negative electrode through which current is received.
- an electrode containing moisture may be used for the first electrode part 111 , the second electrode part 113 , the third electrode part 115 , the fourth electrode part 117 , and the fifth electrode part 119 .
- the present invention is not limited thereto, and the first electrode part 111 , the second electrode part 113 , the third electrode part 115 , the fourth electrode part 117 , and the fifth electrode part 119 may be formed as necessary. It may include a material through which current can be constantly transmitted without moisture.
- the healthcare system 100 may control a transcranial current stimulation (tCS) to be applied from the control unit 140 to the electrode unit 110 .
- tCS transcranial current stimulation
- tDCS transcranial direct current stimulation
- tACS transcranial alternating current stimulation
- tRNS transcranial random-noise stimulation
- the control unit 140 when the recipient wears a healthcare device and starts a healthcare operation, the control unit 140 first performs tACS, and the condition of the recipient becomes a normal state. After that, tDCS is performed. With such a configuration, it is possible to further increase the treatment efficiency for the recipient. This will be described later.
- the power supply unit 120 may supply power required for the operation of the healthcare system 100 according to an embodiment of the present invention through the power used.
- the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , and the fourth electrode unit 117 are positive electrodes, and the fifth electrode unit 119 is a negative electrode.
- the power is supplied so that the first electrode part 111 , the second electrode part 113 , the third electrode part 115 , and the fourth electrode part 117 become negative electrodes, and the fifth electrode part 119 becomes a positive electrode.
- the fifth electrode part Power can be supplied so that 119 becomes a negative electrode.
- the power supplied from the power supply unit 120 to the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , the fourth electrode unit 117 , and the fifth electrode unit 119 is It may be controlled by the controller 140 .
- the power supply unit 120 includes the amount of current supplied to the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , the fourth electrode unit 117 , and the fifth electrode unit 119 . can be adjusted.
- the current flowing through the first electrode part 111 , the second electrode part 113 , the third electrode part 115 , the fourth electrode part 117 , and the fifth electrode part 119 is each electrode. may be about 0.5mA.
- the power supply unit 120 supplies power to the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , the fourth electrode unit 117 , and the fifth electrode unit 119 through commercial power. may be supplied, and may be a battery if necessary. When the power supply unit 120 is a battery, a rechargeable secondary battery may be used.
- the healthcare system 100 may further include a sensor unit 130 for measuring various states of a user.
- the sensor unit 130 may be in close contact with the subject's head at a position different from that of the first to fourth electrode units 111 , 113 , 115 and 117 , for example, the subject's ear. It may be in close contact with an area including at least a portion of the back, the back of the head, and the back of the neck.
- the fifth electrode is preferably located on the right side and the sensor unit on the left side for more effective heart rate measurement.
- a sixth electrode unit may be included at the sensor unit position instead of the sensor unit, and the sixth electrode unit performs the same role as the fifth electrode unit.
- the sensor unit 130 may be an electrocardiogram sensor unit for measuring an electrocardiogram of a recipient.
- the electrocardiogram sensor unit collects human body information of the subject, and checks whether the current applied through the electrode unit 110 causes a problem in the human body.
- the control unit 140 when the recipient wears a healthcare device and starts a healthcare operation, the control unit 140 first performs tACS, and the condition of the recipient becomes normal. It may be configured to perform tDCS afterward, and the electrocardiogram sensor unit serves to determine whether the state of the recipient is normal. Whether the recipient's condition is normal is judged by using the collected information on the ECG in a comfortable condition for the recipient, or information about the normal ECG (for example, resting heart rate by age, etc.) can be used to judge.
- the control unit 140 controls the current flowing through the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , the fourth electrode unit 117 , and the fifth electrode unit 119 . . At this time, the control unit 140 powers only some of the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , the fourth electrode unit 117 , and the fifth electrode unit 119 . can be controlled to be supplied, and can be independently controlled so that each is driven by a positive electrode or a negative electrode.
- the control unit 140 controls the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , and the fourth electrode unit 117 and the fifth electrode unit 119 according to the user's selection.
- the strength of the flowing current can be adjusted.
- the control unit 140 controls the current flowing through the first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , and the fourth electrode unit 117 including the wet or dry pad unit to 0.1 It can be adjusted in the range of mA to 5mA.
- the controller 140 may adjust the current in units of 0.5 mA.
- the controller 140 may automatically adjust the intensity of the current according to the mode, if necessary.
- the control unit 140 receives the human body information of the subject transmitted from the sensor unit 130 .
- the controller 140 may store the received human body information of the subject. Meanwhile, the controller 140 may analyze the received human body information and change the type or intensity of the electrical stimulation transmitted to the electrode unit.
- the controller 140 may further include a communication module (eg, WIFI, Bluetooth, etc.).
- a communication module eg, WIFI, Bluetooth, etc.
- the control unit 140 includes a communication module, it is possible to transmit information about the operation of the healthcare system 100, including human body information of the recipient, to a terminal (eg, a smartphone, computer, etc.) of the recipient.
- a terminal eg, a smartphone, computer, etc.
- information about the mode or the number of times the recipient uses the healthcare system 100 may be transmitted. Accordingly, the recipient may receive a guide on the use of the healthcare system 100 and may receive management of the product.
- the control unit 140 stores various types of electrical stimulation according to the symptoms of the recipient.
- FIGS. 2 to 5 are schematic reference diagrams for explaining various electrical stimulation of the healthcare system according to an embodiment of the present invention.
- FIG. 2 is a reference diagram for explaining the electrical stimulation of the memory and concentration simultaneous improvement mode.
- the control unit 140 drives the first electrode unit 111, the second electrode unit 113, the third electrode unit 115, and the fourth electrode unit 117 as positive electrodes,
- the fifth electrode unit 119 may be controlled to be driven as a negative electrode.
- a sixth electrode unit may be included at a position of the sensor unit instead of the sensor unit, and the sixth electrode unit may be controlled to be driven by a negative electrode in the same manner as the fifth electrode unit.
- FIG. 3 is a reference diagram for explaining electrical stimulation in a memory improvement mode.
- the control unit 140 may control the first electrode unit 111 and the second electrode unit 113 to be driven by a positive electrode and the fifth electrode unit 119 to be driven by a negative electrode.
- the third electrode unit 115 and the fourth electrode unit 117 may be controlled not to operate.
- a sixth electrode unit may be included at a position of the sensor unit instead of the sensor unit, and the sixth electrode unit may be controlled to be driven by a negative electrode in the same manner as the fifth electrode unit.
- FIG. 4 is a reference diagram for explaining electrical stimulation in a concentration improvement mode.
- the control unit 140 may control the third electrode unit 115 and the fourth electrode unit 117 to be driven as a positive electrode and the fifth electrode unit 119 to be driven as a negative electrode.
- the first electrode unit 111 and the second electrode unit 113 may be controlled not to operate. If there is no sensor part, a sixth electrode part may be included at a position of the sensor part instead of the sensor part, and the sixth electrode part may be controlled to be driven by a negative electrode in the same manner as the fifth electrode part.
- FIG. 5 is a reference diagram for explaining electrical stimulation in a sleep mode (insomnia improvement mode).
- the controller 140 drives the first electrode part 111, the second electrode part 113, the third electrode part 115, and the fourth electrode part 117 as negative electrodes, and the fifth electrode part 119 can be controlled to be driven as a positive electrode.
- a sixth electrode unit may be included at a position of the sensor unit instead of the sensor unit, and the sixth electrode unit may be controlled to be driven by a negative electrode in the same manner as the fifth electrode unit.
- the 'insomnia mode' is a mode that can be used when you want to rest your brain.
- the first electrode unit 111 , the second electrode unit 113 , and the third electrode unit 111 to stimulate at least one of the frontal and parietal lobes in order to improve speech ability, spatiotemporal ability, emotion regulation, and auditory ability.
- At least one of the electrode unit 115 and the fourth electrode unit 117 may be driven.
- control unit 140 may include a first electrode unit 111 , a second electrode unit 113 , a third electrode unit 115 , and a fourth electrode unit ( 117) and the current flowing through the fifth electrode unit 119 may be blocked.
- first electrode unit 111 , the second electrode unit 113 , the third electrode unit 115 , and the fourth electrode unit Current flowing through 117 and the fifth electrode unit 119 may be blocked.
- electrical stimulation may be applied as tDCS.
- the modes shown in FIGS. 2 to 5 may be combined to form a program.
- FIG. 6 schematically shows the form of electrical stimulation of tDCS and tACS.
- tDCS direct current
- tACS uses alternating current and applies a rectangular (dotted line) or sinusoidal (solid line) stimulus.
- tDCS regulates spontaneous neural activity in the brain through polarized electrical stimulation. For example, it is effective in the regulation of decision-making, memory, language, sensory perception, etc. for each part of the brain.
- tACS uses alternating current, it is practically impossible to control the directionality (eg, up or down) of currents in brain regions. Therefore, tDCS is more widely used than tACS for the prevention, treatment and management of depression, convulsive disease, pain, intellectual disability, addictive disease and mild cognitive impairment, and improvement of memory and motor learning ability.
- tDCS has a problem in that the treatment effect decreases due to fatigue or stress of the operator.
- tDCS causes discomfort such as stinging pain in the skin at the beginning of the procedure, and this discomfort reduces the periodic and long-term availability of the recipient's health care system, and even if used, there is a problem that increases the stress of the recipient.
- the subject's anxiety and tension increase.
- the discomfort of tDCS further increases the subject's anxiety and tension.
- the healthcare system 100 proposes a program configured to solve the above-described problems of tDCS.
- FIG. 7 is a reference diagram for explaining a check mode, a buffer mode, and a main mode of the healthcare system according to an embodiment of the present invention.
- the controller 140 When the recipient selects any one of the programs provided by the healthcare system, the controller 140 first performs a check mode.
- the check mode confirms whether the recipient properly wears a health care device, which will be described later.
- the resistance of the electrode part 110 is measured, and an appropriate action is guided to the recipient according to the range of the resistance value. For example, when the impedance of the electrode part is lower than the installed load, it is normal, and when the impedance of the load and the electrode part is in the range of 1-2 times, it is due to lack of moisture in the wet pad, and the load is the electrode. When the negative impedance exceeds twice, it may be determined as poor adhesion of the electrode part.
- a buffer mode is performed.
- the buffer mode uses tACS to adapt the skin in contact with the electrode, thereby lowering skin irritation caused by tDCS in the main mode.
- electrical stimulation 4 to 40 Hz can be used.
- the buffer mode (mode 0) may use tACS (alpha).
- tACS(alpha) is 8 ⁇ 12Hz As a means of electrical stimulation, it has the effect of relieving the tension of the recipient. Therefore, if the buffer mode is performed first and then the main mode is performed, the treatment effect of the main mode is further increased.
- the main mode consists of at least one of a memory improvement mode, a concentration improvement mode, a memory improvement and concentration simultaneous improvement mode, and a sleep mode.
- the main mode consists of ramp up-stimulation-ramp down. By locating the ramp-up step in the first half of the stimulation of the main mode, enough time is given to adapt to the skin stimulation of the recipient, thereby reducing discomfort.
- FIG. 8 is a schematic reference diagram illustrating various examples of programs of the healthcare system 100 according to an embodiment of the present invention.
- mode I memory improvement mode
- mode II concentration improvement mode
- mode III concentration simultaneous improvement mode
- mode IV sleep mode
- memory improvement mode mode I
- concentration improvement mode mode II
- memory and concentration simultaneous improvement mode mode III
- sleep mode mode IV
- 8(b) and 8(c) are characterized in that the buffer mode (mode 0) using tACS is performed at the beginning of the program.
- each mode A buffer mode may be positioned between them to relieve tension of the recipient.
- the impedance may increase due to evaporation of moisture from the wet pad with body temperature during use.
- the control unit 140 may measure the ECG change of the subject according to the execution of the buffer mode (mode 0) by using the sensor unit 130 .
- the main mode using tDCS the patient's tension is increased due to the pain caused by electrical stimulation, and accordingly, the electrocardiogram is changed.
- the controller 140 may start the scheduled main mode operation when it is determined that the ECG is in a normal state by sensing the ECG change of the recipient while operating the buffer mode (mode 0).
- the ECG When the ECG is in a normal state, it means an ECG measurement value in a comfortable state of the recipient, and can be determined based on the heart rate or rhythm.
- Each mode composing the program is usually performed for 10 to 30 minutes, but if necessary, it can be performed for less than 1 hour, and the intensity is determined within -5 mA to +5 mA.
- the amplitude can be controlled within -1mA to +1mA.
- the buffer mode (mode 0) allows the amplitude to gradually increase as time passes so that the skin of the recipient can more smoothly adapt to the stimulus.
- Table 1 below is a summary of the results of a survey for the recipients after the procedure according to each program of FIG. 8 .
- a comparative example is a survey result for 100 people who used the healthcare system according to the program of FIG. 8(a), and Example 1 is about 100 people who used the healthcare system according to the program of FIG. It is a survey result, and Example 2 is a survey result for 100 people who used the health care system according to the program of FIG. 8(c).
- the rate of feeling discomfort such as a stinging pain at the initial stage of the program operation of the healthcare system 100 according to an embodiment of the present invention is 82% in Comparative Example, 23% in Example 1, and In the case of Example 2, it was only 8%. In particular, in the case of Example 2, it was answered that the degree of pain was very mild. In the case of satisfaction with the healthcare system according to an embodiment of the present invention, all of them showed relatively high satisfaction, but Examples 1 and 2, in which the degree of pain was mild, showed higher satisfaction.
- FIGS. 9 to 11 are quantitative EEG data before and after the procedure of the healthcare system according to an embodiment of the present invention.
- 9 is a quantitative EEG data before and after the operation of a person who is addicted to games at a high level
- FIG. 10 is a quantitative EEG data before and after the operation of a person who has tic disorder and ADHD symptoms
- FIG. It is quantitative EEG data.
- FIGS. 9 to 11 it can be seen that abnormal EEG (dark color) appeared before the procedure, and normal EEG (light color) was restored after the procedure.
- the non-invasive brain stimulation healthcare system as described above may be implemented as a program (or application) including an executable algorithm that can be executed on a computer.
- the program may be provided by being stored in a non-transitory computer readable medium.
- the non-transitory readable medium refers to a medium that stores data semi-permanently, rather than a medium that stores data for a short moment, such as a register, a cache, a memory, and the like, and can be read by a device.
- a non-transitory readable medium such as a CD, DVD, hard disk, Blu-ray disk, USB, memory card, ROM, and the like.
- Non-invasive brain stimulation healthcare device includes
- FIG. 12 is a schematic side view of a healthcare device in which a healthcare system according to an embodiment of the present invention is implemented
- FIG. 13 is a schematic rear view of a healthcare device according to another embodiment of the present invention
- FIG. 14 is the present invention is a schematic bottom view of a healthcare device according to another embodiment.
- 15 (a) is a schematic plan view of an upper electrode adhesion module of a healthcare device according to another embodiment of the present invention
- FIG. 15 (b) is a view inside the helmet of the healthcare device according to another embodiment of the present invention.
- FIG. 16 is a schematic plan view of a lower electrode adhesion module of a healthcare device according to another embodiment of the present invention.
- a health care device includes a helmet 210 having a dome shape so as to be worn on the head of a recipient, and a plurality of electrode parts 251, 253, 255, 257 installed inside the helmet 210, 259).
- an additional electrode unit may be further included.
- the above-described power supply unit 120, sensor unit 130, and control unit 140 may also be mounted on the helmet 210, and the user attaches the mild cognitive impairment prevention health care system 100 to the outer surface of the helmet 210.
- An operation unit that can be operated may be installed.
- the user when the user wears the helmet 210 and selects a mode to be used, the user can use the helmet 210 for a set time (eg, about 20 minutes at a time).
- a set time eg, about 20 minutes at a time.
- the helmet 210 includes a first frame 211 formed to cover from the forehead to the back of the head of the wearer and having openings 213 and 214 in the upper portion, and the first frame 211 extending upwardly from the first frame 211 to the recipient's head. Consists of a second frame 212 that crosses the top of the head. The opening of the upper portion of the first frame 211 is divided into a first opening 213 and a second opening 214 by the second frame 212 .
- the power supply unit 120 and the control unit 140 of the healthcare system 100 are installed inside the frames 211 and 212 of the helmet 210 .
- a button 220 is installed on the outside of the helmet 210 to control power and operation of the healthcare system 100 .
- the control unit 140 includes a communication module, it is also possible for the recipient to control the healthcare system 100 using his/her own smartphone or the like.
- the helmet 210 may further include a short-range communication module capable of performing short-range wireless communication such as Bluetooth, such as a smartphone or tablet PC used by the user. Therefore, the user can check and control the operation of the mild cognitive impairment prevention health care system using a smartphone or tablet PC.
- a short-range communication module capable of performing short-range wireless communication such as Bluetooth, such as a smartphone or tablet PC used by the user. Therefore, the user can check and control the operation of the mild cognitive impairment prevention health care system using a smartphone or tablet PC.
- the helmet 210 may be installed with an external communication module that can connect to the Internet. Therefore, the information on the electrocardiogram measured by the sensor unit 130 can be transmitted to the hospital used by the user through the Internet network, and information about the mode or number of times the user uses the mild cognitive impairment prevention health care system. can transmit Accordingly, the user may receive guidance on the use of the mild cognitive impairment prevention health care system, and may receive management of the product.
- a plurality of electrode units 251 , 253 , 255 , 257 and 259 are installed inside the helmet 210 .
- the electrode unit In order to operate the mode or program of the health care system 100 to the recipient using the healthcare device 200 according to another embodiment of the present invention, the electrode unit must be in close contact with the recipient's head.
- the healthcare device 200 includes an upper electrode adhesion module 230 and a lower electrode adhesion module 240 installed on the helmet 210 .
- the upper electrode adhesion module 230 includes a first band adjusting unit 232 installed with a fixed position on the helmet 210, a first band 233 having a length adjusted by the first band adjusting unit 232, and a second It includes a first electrode unit 251 and a second electrode unit 253 installed on the first band 233 .
- the first band 233 constitutes a ring along the head of the recipient on the inside of the helmet 210 .
- the length of the first band 233 may be adjusted by manipulating the first dial 231 of the first band adjusting unit 232 .
- the length of the first band 233 is shortened, and when the first dial 231 is turned counterclockwise (or clockwise), The length of the first band 233 is increased.
- the present invention is not limited thereto, and it is also possible to borrow another method (eg, an electric motor) capable of adjusting the length of the first band 233 .
- a first electrode socket 235 and a second electrode socket 236 are installed on the first band 233 .
- At least one electric wire 234 is built in the first band 233 , and the electric wire is connected to the first electrode socket 235 and the second electrode socket 236 , respectively.
- the first electrode part 251 is connected to the first electrode socket 235
- the second electrode part 253 is connected to the second electrode socket 236 .
- the first electrode socket 235 and the second electrode socket 236 may be configured in plurality, respectively, and the first electrode socket 235 and the second electrode socket ( The first electrode unit 251 and the second electrode unit 253 may be provided on the 236 .
- the third electrode part 255 and the fourth electrode part 257 are installed inside the helmet 210 and on the back of the head of the recipient (near the parietal lobe).
- the third electrode part 255 and the fourth electrode part 257 also have a plurality of sockets (not shown) installed inside the helmet 210 like the first electrode part 251 and the second electrode part 253 . and the third electrode part 255 and the fourth electrode part 257 are installed at appropriate positions among the sockets.
- the third electrode part 255 and the fourth electrode part 257 are installed in a position where they can be in close contact with an area including at least some of the parietal, occipital, and temporal lobe sides of the first band 233 of the recipient.
- an additional band adjusting part capable of adjusting the length of the first band may be installed in the middle of the first band (between the first electrode part and the third electrode part, and between the second electrode part and the fourth electrode part).
- the additional band adjuster may use a known technique to increase or decrease the length of the band.
- the recipient wears the helmet 210 in a state where all the electrodes are installed inside the helmet and the first band 233 is made long. Then, when the recipient manipulates the first dial to reduce the length of the first band 233, the first band 233 in a state where the third electrode part 255 and the fourth electrode part 257 support the back head of the recipient. ), the first electrode part 251 and the second electrode part 253 are in close contact with the frontal part of the recipient, that is, the frontal lobe part.
- the recipient inserts the electrode into the socket at an appropriate location and operates the first dial, the first electrode 251, the second electrode 253, the third electrode 255, and the fourth electrode 257 can be easily attached to the head.
- the first electrode unit 251 may include a pad receiving unit 251a and a wet pad 251b, or a dry pad formed of a multilayer hydrogel composite may be used. Such a configuration may be similarly applied to the second to fifth electrode units 253 , 255 , 257 , and 259 .
- the first electrode unit 251 will be described as an example.
- the recipient uses the sponge pad 251b after soaking it in water. This is the same for other electrode parts other than the first electrode part 251 . Therefore, when using the healthcare device 200 according to another embodiment of the present invention, moisture is evaporated by body temperature. becomes this The health care device 200 according to another embodiment of the present invention forms the first opening 213 and the second opening 214 on the top of the helmet 210, thereby discharging moisture or water vapor generated during use to the outside. Prevents discomfort and odor problems of the recipient due to moisture.
- the lower electrode adhesion module 240 includes a second band adjusting unit 242 installed independently of the helmet 210 , a second band 243 having a length adjusted by the second band adjusting unit 242 , and a second band and a fifth electrode part 259 installed at 243 .
- a sensor unit 260 may be further installed on the second band 243 .
- the second band 243 is a region including at least a portion of the back of the recipient's ear, the back of the head, and the back of the neck. It is configured to partially wrap. If the present healthcare system does not include the sensor unit, a sixth electrode unit may be included at the position of the sensor unit instead of the sensor unit, and the sixth electrode unit performs the same role as the fifth electrode unit.
- the end of the second band 243 is fixed to the helmet 210 .
- the length of the second band 243 may be adjusted by manipulating the second dial 241 of the second band adjusting unit 242 .
- the length of the second band 243 is shortened, and when the second dial 241 is turned counterclockwise (or clockwise), the length of the second band 243 is shortened.
- the length of the second band 243 is increased.
- the present invention is not limited thereto, and it is also possible to borrow another method (eg, an electric motor) capable of adjusting the length of the second band 243 .
- a fifth electrode socket 245 is installed on the second band 243 .
- the sensor unit socket 246 may be further installed in the second band 243 .
- At least one electric wire 244 is built in the second band 243 , and the electric wire is connected to the fifth electrode socket 245 and the sensor unit socket 246 , respectively.
- the fifth electrode unit 259 is connected to the fifth electrode socket 245
- the sensor unit 260 is connected to the sensor unit socket 246 .
- the fifth electrode socket 245 and the sensor part socket 246 may be configured in plurality, respectively, and the fifth electrode socket 245 and the sensor part socket 246 at positions suitable for the person's head.
- the fifth electrode unit 259 and the sensor unit 260 may be installed on the .
- the recipient manipulates the second dial 241 of the lower electrode adhesion module 240 to obtain the second electrode.
- the length of the 2 band 243 is reduced.
- the fifth electrode unit 259 or the sensor unit 260 covers an area including at least a part of the recipient's ear, back, and back neck. It is configured to partially wrap.
- the sensor unit it is also possible to use a sensor unit of a known electrocardiogram sensor.
- the helmet 210 may further include an LED monitoring unit (not shown).
- the LED monitoring unit consists of 5 or 6 LEDs, and serves to display the operating status of the electrode unit or the sensor unit (whether the current value/resistance value is satisfied, etc.).
- an anti-contamination coating layer made of an anti-contamination coating composition may be applied to the outer surface of the electrode part to effectively prevent adhesion of and remove pollutants.
- the antifouling coating composition contains mercaptobenzothiazole and amidoalkyl betaine in a molar ratio of 1:0.01 to 1:2, and the total content of mercaptobenzothiazole and amidoalkylbetaine is 1 based on the entire aqueous solution. ⁇ 10% by weight.
- the molar ratio of mercaptobenzothiazole and amidoalkyl betaine is preferably 1:0.01 to 1:2.
- the applicability of the substrate decreases or moisture adsorption on the surface increases after application. There is a problem that the membrane is removed.
- the mercaptobenzothiazole and amidoalkyl betaine are preferably 1 to 10% by weight in the entire aqueous solution of the composition, and when less than 1% by weight, there is a problem in that the applicability of the substrate is reduced, and when it exceeds 10% by weight, the thickness of the coating film Crystal precipitation is likely to occur due to an increase in
- the thickness of the final coating film on the substrate is preferably 550 to 2000 ⁇ , more preferably 1100 to 1900 ⁇ . If the thickness of the coating film is less than 550 ⁇ , there is a problem in that it is deteriorated in the case of high-temperature heat treatment, and if it exceeds 2000 ⁇ , there is a disadvantage that crystal precipitation on the coated surface is easy to occur.
- the present antifouling coating composition may be prepared by adding 0.1 mol of mercaptobenzothiazole and 0.05 mol of amidoalkyl betaine to 1000 ml of distilled water and then stirring.
- fragrance material having a sterilizing function is coated on the inner and outer surfaces of the helmet 210, it effectively sterilizes (relieves stress) the inner and outer surfaces of the helmet 210 .
- functional oil may be mixed with the fragrance material, and the mixing ratio is 95 to 97% by weight of the functional oil and 3 to 5% by weight of the functional oil, and the functional oil is 50% by weight of Costus oil, Cassii Oil (Cassie oil) consists of 50% by weight.
- the functional oil is preferably mixed in an amount of 3 to 5% by weight with respect to the fragrance. If the mixing ratio of the functional oil is less than 3% by weight, the effect is insignificant, and if the mixing ratio of the functional oil exceeds 3 to 5% by weight, the effect is not greatly improved, while the manufacturing cost is greatly increased.
- Costus oil has good effects on neuralgia, muscle pain, antidepression, and stress relief.
- Cassie oil is effective in detoxifying, treating skin diseases, sterilizing, relieving itching, clearing the head, and relieving tension.
- an adhesion enhancer is applied to improve adhesion when the first to fifth electrode parts 111, 113, 115, 117, and 119 are attached to the inner surface of the helmet 210, and the adhesion enhancer is 53 parts by weight of water; 15 parts by weight of ethyl acrylate, 20 parts by weight of butyl acrylate, 3 parts by weight of toyltriazole, 5 parts by weight of a surfactant, 1 part by weight of an additive, 2 parts by weight of ammonium persulfate, and 1 part by weight of a buffer can be configured.
- the solvent water
- the overall concentration becomes high and the spray operation becomes difficult. It is preferably added in 53 parts by weight.
- the ethyl acrylate When the ethyl acrylate is added in an amount of 15 parts by weight based on 100 parts by weight of the total, flexibility and water resistance are lowered, so it is not easy to mix with water as a solvent. It is preferable to add in 15 parts by weight as it becomes a factor of making spraying difficult.
- the surfactant uses both anionic and nonionic types and uses a commonly known conventional material that is uniformly mixed by dispersing monomers in water.
- the hydrophilicity and lipophilicity between water and the monomer are lowered, so mixing and homogenization is difficult, and when 5 parts by weight or more is added based on 100 parts by weight of the total, the effect of hydrophilicity and lipophilicity between the solvent water and the monomer can no longer be expected. It is preferable to add it in parts.
- the additive is a general stabilizer that helps maintain the continuous physical properties of the product, and is preferably added in 1 part by weight.
- ammonium persulfate When the catalyst, ammonium persulfate, is added in an amount of less than 2 parts by weight based on 100 parts by weight of the total, the reaction does not occur smoothly between the monomers, so it is difficult to obtain good physical properties. It is preferable to add in 2 parts by weight as this is a factor that causes deterioration of physical properties.
- the buffer is preferably added in an amount of 1 part by weight based on 100 parts by weight of the total that does not affect the overall physical properties and viscosity.
- the first to fifth electrode parts according to the present invention are performed by performing an aging step of aging for about 90 minutes while maintaining the temperature of the reactor at 72°C, and then performing a cooling step of cooling at room temperature. (111, 113, 115, 117, 119) and the manufacturing process of the adhesion enhancer for improving the adhesion between the inner surface of the helmet 210 is completed.
Abstract
Description
통증을 느낀 비율 | 만족도 | |
비교예 | 82% | 81% |
실시예 1 | 23% | 97% |
실시예 2 | 8% | 98% |
Claims (12)
- 피시술자의 뇌에 전기적인 자극을 가하는 복수의 전극부;상기 복수의 전극부에 전원을 공급하는 전원부; 및상기 복수의 전극부 및 전원부를 제어하여 상기 피시술자의 뇌에 가하지는 전기적 자극을 제어하는 제어부;를 포함하고,상기 전기적인 자극은 tACS를 이용하는 버퍼모드와 tDCS를 이용하는 메인모드를 포함하는 비침습적 뇌자극 헬스케어 장치.
- 제1항에 있어서,상기 버퍼모드는 상기 메인모드의 수행 전에 수행되는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제1항에 있어서,피시술자의 심전도를 측정하는 센서부를 더 포함하는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제3항에 있어서,상기 버퍼모드가 수행되는 경우 상기 제어부는 상기 센서부로부터 상기 피시술자의 심전도에 관한 정보를 수집하고,상기 제어부는 상기 피시술자의 심전도에 관한 정보를 분석하여 피시술자가 정상상태인 경우 상기 버퍼모드를 종료하고 상기 메인모드를 수행하는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제1항에 있어서,상기 복수의 전극부는,상기 피시술자의 뇌 중 좌측 전두엽(frontal lobe)에 전기적인 자극을 가하기 위한 제1전극부;상기 피시술자의 뇌 중 우측 전두엽에 전기적인 자극을 가하기 위한 제2 전극부;상기 피시술자의 뇌 중 좌측 두정엽(parietal lobe)에 전기적인 자극을 가하기 위한 제3 전극부;상기 피시술자의 뇌 중 우측 두정엽에 전기적인 자극을 가하기 위한 제4 전극부; 및상기 피시술자의 머리에 배치되고 상기 제1 내지 제4 전극부와 다른 극성을 갖는 제5 전극부를 포함하는 비침습적 뇌자극 헬스케어 장치.
- 제1항에 있어서,상기 피시술자의 머리에 쓸 수 있도록 돔 형상을 갖고 상기 복수의 전극부가 배치되는 헬멧; 및상기 헬멧에 설치되는 상부전극 밀착모듈;을 포함하고,상기 상부전극 밀착모듈은,상기 헬멧에 위치가 고정되어 설치되는 제1밴드조절부; 및상기 제1밴드조절부에 의해 길이가 조절되며, 상기 헬멧의 내측에서 피시술자의 머리를 감싸도록 고리로 구성되는 제1밴드;를 포함하고,상기 복수의 전극부 중 적어도 일부는 상기 제1밴드에 설치되며, 상기 제1밴드조절부에 의해 상기 제1밴드의 길이가 짧아질 경우 상기 제1밴드에 설치된 전극부가 피시술자의 전두엽 측에 밀착되는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제6항에 있어서,상기 복수의 전극부 중 적어도 일부는 상기 헬멧의 내측 후방에 설치되며, 상기 제1밴드조절부에 의해 상기 제1밴드의 길이가 짧아질 경우 상기 헬멧 내측 후방에 설치된 전극부가 피시술자의 두정엽측, 후두엽측 및 측두엽측 중 적어도 일부를 포함하는 영역에 밀착되어 지지하는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제6항에 있어서,상기 복수의 전극부 중 다른 일부는 상기 제1밴드 중 피시술자의 두정엽측, 후두엽측 및 측두엽측 중 적어도 일부를 포함하는 영역에 밀착될 수 있는 위치에 설치되는 것을 비침습적 뇌자극 헬스케어 장치.
- 제6항에 있어서,상기 헬멧에 설치되는 하부전극 밀착모듈을 더 포함하고,상기 하부전극 밀착모듈은,상기 헬멧과 독립적으로 설치되는 제2밴드조절부; 및상기 제2밴드조절부에 의해 길이가 조절되며, 피시술자의 뒷목 또는 귀 뒤쪽 부위를 일부 감싸도록 구성되는 제2밴드;를 포함하고,상기 복수의 전극부 중 일부는 상기 제2밴드에 설치되며, 상기 제2밴드조절부에 의해 상기 제2밴드의 길이가 짧아질 경우 상기 제2밴드에 설치된 전극부가 피시술자의 귀 뒤쪽, 뒷통수 및 뒷목 중 적어도 일부를 포함하는 영역에 밀착되는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제9항에 있어서,상기 제2밴드에 설치되는 센서부를 더 포함하고,상기 제2밴드조절부에 의해 상기 제2밴드의 길이가 짧아질 경우 상기 센서부가 피시술자의 귀 뒤쪽, 뒷통수 및 뒷목 중 적어도 일부를 포함하는 영역에 밀착되는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제6항에 있어서,상기 전극부는 습식패드를 포함하고,상기 헬멧은 이마로부터 뒷통수까지 감싸도록 형성되되 상부에 개구를 가지는 제1프레임과, 상기 제1프레임으로부터 상부로 연장되어 피시술자의 머리 위쪽을 가로지르는 제2프레임을 포함하며,상기 습식패드에서 발생되는 습기 내지 수분이 상기 개구를 통해 배출되는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
- 제6항에 있어서,상기 헬멧에는 상기 전극부의 동작 상태를 표시하는 LED 모니터링부가 설치되는 것을 특징으로 하는 비침습적 뇌자극 헬스케어 장치.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/636,914 US20220313994A1 (en) | 2020-04-21 | 2021-04-19 | Non-invasive brain stimulation health care device |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0048016 | 2020-04-21 | ||
KR1020200048016A KR102505639B1 (ko) | 2020-04-21 | 2020-04-21 | 뇌 자극 장치 |
KR10-2021-0019603 | 2021-02-15 | ||
KR1020210019603A KR102516618B1 (ko) | 2021-02-15 | 2021-02-15 | 전극 밀착성 및 착용성이 향상된 비침습적 뇌자극 헬스케어 장치 |
KR1020210019604A KR102552199B1 (ko) | 2021-02-15 | 2021-02-15 | 피시술자의 긴장도를 완화시킬 수 있는 비침습적 뇌자극 헬스케어 시스템 |
KR10-2021-0019604 | 2021-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021215769A1 true WO2021215769A1 (ko) | 2021-10-28 |
Family
ID=78269492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/004893 WO2021215769A1 (ko) | 2020-04-21 | 2021-04-19 | 비침습적 뇌자극 헬스케어 장치 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20220313994A1 (ko) |
WO (1) | WO2021215769A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023163543A1 (ko) * | 2022-02-28 | 2023-08-31 | 뉴로엔(주) | 비침습적 자극 장치 및 방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130345774A1 (en) * | 2010-12-28 | 2013-12-26 | Ebs Technologies Gmbh | Device for non-invasive, electrical deep-brain stimulation |
KR20140052781A (ko) * | 2012-10-25 | 2014-05-07 | 계명대학교 산학협력단 | 실시간 뇌 혈류 반응을 이용한 뇌 자극 시스템 |
KR101465597B1 (ko) * | 2014-09-03 | 2014-11-27 | (주)와이브레인 | 경두개 교류 자극(tACS) 장치 |
KR101566786B1 (ko) * | 2015-06-23 | 2015-11-06 | (주)와이브레인 | 전기 자극 및 생체 전위 측정 장치 |
KR101758903B1 (ko) * | 2015-10-22 | 2017-07-18 | (주)와이브레인 | 경두개 직류 자극(tDCS) 장치 |
-
2021
- 2021-04-19 WO PCT/KR2021/004893 patent/WO2021215769A1/ko active Application Filing
- 2021-04-19 US US17/636,914 patent/US20220313994A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130345774A1 (en) * | 2010-12-28 | 2013-12-26 | Ebs Technologies Gmbh | Device for non-invasive, electrical deep-brain stimulation |
KR20140052781A (ko) * | 2012-10-25 | 2014-05-07 | 계명대학교 산학협력단 | 실시간 뇌 혈류 반응을 이용한 뇌 자극 시스템 |
KR101465597B1 (ko) * | 2014-09-03 | 2014-11-27 | (주)와이브레인 | 경두개 교류 자극(tACS) 장치 |
KR101566786B1 (ko) * | 2015-06-23 | 2015-11-06 | (주)와이브레인 | 전기 자극 및 생체 전위 측정 장치 |
KR101758903B1 (ko) * | 2015-10-22 | 2017-07-18 | (주)와이브레인 | 경두개 직류 자극(tDCS) 장치 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023163543A1 (ko) * | 2022-02-28 | 2023-08-31 | 뉴로엔(주) | 비침습적 자극 장치 및 방법 |
Also Published As
Publication number | Publication date |
---|---|
US20220313994A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6856704B2 (ja) | 医学的障害の治療のためのデバイス | |
US20200147340A1 (en) | Systems and methods for transdermal electrical stimulation to improve sleep | |
KR101749607B1 (ko) | 신경정신병학적 장애들의 치료를 위한 시스템, 장치 및 방법 | |
WO2017197150A1 (en) | Device, system and method for mechanical cutaneous nerve stimulation for pain, stroke, mood, breathing, movement, sleep, and vascular action | |
WO2021215769A1 (ko) | 비침습적 뇌자극 헬스케어 장치 | |
WO2021091008A1 (ko) | 가시광선을 이용하여 감마 대역의 뇌파를 활성화하는 방법 및 이를 위한 시각 자극 제공 장치 | |
WO2021187877A1 (ko) | 개인 맞춤형 이명 치료를 위한 장치 및 이를 수행하기 위한 컴퓨터 판독 가능한 기록 매체 | |
US20230110636A1 (en) | Method and device for improving brain function | |
US20240066315A1 (en) | Therapeutic devices and methods to improve body functions | |
Kappel et al. | Real-life dry-contact ear-EEG | |
US20220211319A1 (en) | Non-invasive proprioceptive stimulation for treating epilepsy | |
CN108434595B (zh) | 一种头带式脑部电刺激仪及其电刺激方法 | |
Attias et al. | Efficacy of self-hypnosis for tinnitus relief | |
Katch | Applications of transcutaneous electrical nerve stimulation in dentistry | |
CA2455573A1 (en) | Method and apparatus to modify cranial electrical potentials to remediate psychiatric disorders and to enhance optimal brain functioning | |
WO2022059819A1 (ko) | 표면 근전도 센서를 이용한 졸음 방지 마사지 장치 및 개인 맞춤형 졸음 판단 방법 | |
WO2023163547A1 (ko) | 비침습적 자극 장치 | |
WO2023163543A1 (ko) | 비침습적 자극 장치 및 방법 | |
KR102552199B1 (ko) | 피시술자의 긴장도를 완화시킬 수 있는 비침습적 뇌자극 헬스케어 시스템 | |
KR20190067547A (ko) | 저주파 전기 자극 치료기 | |
KR102516618B1 (ko) | 전극 밀착성 및 착용성이 향상된 비침습적 뇌자극 헬스케어 장치 | |
Repitsch et al. | Functional electrical stimulation in facial rehabilitation | |
KR20210129909A (ko) | 경도인지장애 예방 헬스 케어 시스템 | |
US20220096318A1 (en) | Device, system and method for reducing headache pain | |
WO2024039008A1 (ko) | 생체신호 측정에 따른 증상 정도를 반영한 미주신경에 대한 전기자극 인가 방법 및 전기자극 인가 장치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21791839 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21791839 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 11/04/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21791839 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21791839 Country of ref document: EP Kind code of ref document: A1 |